Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea

Postoperative Nausea and Vomiting Are Similar When Propofol or Sevoflurane Are Used as Adjuvant to Remifentanil During Anaesthesia for Gynaecological Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00452855

Enrollment

160

Registered

2007-03-28

Start date

2002-01-31

Completion date

2005-05-31

Last updated

2007-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea, Vomiting

Keywords

Nausea, Vomiting, Post operative, Propofol remifentanil anaesthesia, Sevoflurane remifentanil anaesthesia

Brief summary

The purpose of this study is to determine whether sevoflurane-remifentanil anaesthesia is similar to propofol-remifentanil anaesthesia concerning post- operative nausea and vomiting.

Detailed description

Propofol and sevoflurane anaesthesia are used world wide at the anaesthetists discretion. Propofol is superior to inhalational anaesthetics as anaesthesia for patients at risk of post operative nausea and vomiting (PONV) as PONV is diminished. However, when remifentanil is used as adjuvant to sevoflurane, the total dose of the latter is reduced. Therefore, we wanted to investigate if sevoflurane-remifentanil anaesthesia is similar to propofol-remifentanil anaesthesia with emphasis on nausea, vomiting and total PONV during 24 hours. In the post anaesthesia care unit (PACU) and in the surgical ward nausea was scored on a visual analogue score. Vomiting was registered.

Interventions

PROCEDURESevoflurane-remifentanil anaesthesia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 50 Years

Healthy volunteers

Inclusion criteria

* Females younger than 50 years * ASA I-II * Scheduled to gynaecological laparotomies or laparoscopies

Exclusion criteria

* Medication known to act anti-emetic * ASA status greater than II * Malignant hyperthermia * Allergy to the drugs used.

Design outcomes

Primary

Measure	Time frame
Nausea, incidence and intensity ( VAS score )in PACU and surgical ward	—
Vomiting, incidence in PACU and surgical ward	—
Total PONV after 24 hours	—

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026